GBP5 increases lung cancer infiltration of B cells, CD4+ and CD8+ T cells, and NK cells, potentially sensitizing tumors to PD-L1 blockade or other immunotherapies, mediated by its Golgi localization and interferon-driven immune checkpoint modulation [59]. The gene discussed is CD8A; the disease is lung carcinoma.